Dianthus Therapeutics, Inc.
NASDAQ:DNTHBiotechnology
Healthcare
$84.83 -1.25%
-$1.03 today
- Market cap
- $4.78B
- Beta
- 0.07
- P/E (TTM)
- -343.0
- EPS (TTM)
- -$0.24
52W Low $16.64High $96.50
Volume 0.89M
Average 0.82M
Balance Sheet
Inspect the capital base behind the business.
Assets
$530.92M
FY 2025 · Annual
+42.0% YoYLiabilities
$37.52M
FY 2025 · Annual
+74.3% YoYEquity
$493.40M
FY 2025 · Annual
+40.0% YoYBalance Sheet
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 131.65M | 15.37M | 132.33M | 22.79M | 51.09M |
| Short-term Investments | 45.28M | 60.13M | 41.39M | 252.45M | 353.21M |
| Net Receivables | 0 | 5.64M | 478K | 807K | 102K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 3.77M | 53K | 504K | 355K | 5.04M |
| Total Current Assets | 180.69M | 82.03M | 177.45M | 280.9M | 409.44M |
| Property, Plant & Equipment (Net) | 7.46M | 956K | 800K | 1.75M | 1.63M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 1.78M | 0 | 0 | 81.73M | 110.14M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 121K | 1.15M | 9.63M | 9.72M |
| Total Non-current Assets | 9.24M | 1.08M | 1.95M | 93.1M | 121.48M |
| Total Assets | 189.93M | 83.11M | 179.41M | 374.01M | 530.92M |
| Account Payables | 3.04M | 1.17M | 2.61M | 4.58M | 9.73M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 100K | 100K | 479K | 1.19M |
| Other Current Liabilities | 4.48M | 2.08M | 5.36M | 5.15M | 9.52M |
| Total Current Liabilities | 10.86M | 8.23M | 9.63M | 18.45M | 30.73M |
| Long-term Debt | 0 | 0 | 0 | 0 | 1.02M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 791K | 736K | 1.91M | 5.77M |
| Other Non-current Liabilities | 6.4M | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 6.4M | 1.23M | 904K | 3.08M | 6.79M |
| Total Liabilities | 17.26M | 9.45M | 10.54M | 21.53M | 37.52M |
| Common Stock | 59K | 0 | 15K | 31K | 43K |
| Retained Earnings | (325.57M) | (45.87M) | (89.42M) | (174.39M) | (336.73M) |
| Accumulated OCI | (30K) | (161K) | 47K | 106K | 489K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 172.67M | 73.66M | 168.87M | 352.48M | 493.4M |
| Total Debt | 0 | 788K | 585K | 1.49M | 1.39M |
| Net Debt | (131.65M) | (14.58M) | (131.74M) | (21.3M) | (49.7M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $110.5M |
| Short-term Investments | $776.3M |
| Receivables | $106.0K |
| Other Current | $10.6M |
| Total Current Assets | $897.5M |
| PP&E (Net) | $1.6M |
| Long-term Investments | $303.6M |
| Other Non-current | $10.5M |
| Total Non-current Assets | $315.7M |
| Total Assets | $1.2B |
Analysis
Selected assets total $1.2B for Latest. The largest visible component is Short-term Investments at $776.3M, about 64.0% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| 8-K | Current report | Nov 4, 2026 | |
| 10-Q | Quarterly report | Nov 4, 2026 | |
| SC 13G | SC 13G filing | Oct 30, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 18, 2026 |
How much cash does DNTH have?
Dianthus Therapeutics, Inc. (DNTH) reported $51.09M in cash and equivalents in fiscal 2025.
How much debt does DNTH carry?
Dianthus Therapeutics, Inc. (DNTH) reported $1.39M of total debt, with net debt of -$49.70M.
Continue the stock analysis
Jump to another research area for this company.